Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Lilly points in a new radiopharma direction
After being burned by Point, Lilly is taking a slower approach with Radionetics.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
Merck KGaA’s xevinapant gets SMACked down
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
